Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
Alou L, Giménez MJ, Sevillano D, Aguilar L, Cafini F, Echeverría O, Pérez-Trallero E, Prieto J. Alou L, et al. Among authors: gimenez mj. J Antimicrob Chemother. 2006 Aug;58(2):349-58. doi: 10.1093/jac/dkl250. Epub 2006 Jun 16. J Antimicrob Chemother. 2006. PMID: 16782744
Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation.
Sevillano D, Calvo A, Giménez MJ, Alou L, Aguilar L, Valero E, Carcas A, Prieto J. Sevillano D, et al. Among authors: gimenez mj. J Antimicrob Chemother. 2004 Dec;54(6):1148-51. doi: 10.1093/jac/dkh463. Epub 2004 Oct 15. J Antimicrob Chemother. 2004. PMID: 15489246
Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers.
Alou L, Aguilar L, Sevillano D, Giménez MJ, Laguna B, Echeverría O, Carcas A, Lubomirov R, Casal J, Prieto J. Alou L, et al. Among authors: gimenez mj. J Antimicrob Chemother. 2005 May;55(5):742-7. doi: 10.1093/jac/dki071. Epub 2005 Mar 10. J Antimicrob Chemother. 2005. PMID: 15761068 Clinical Trial.
Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration.
Alou L, Aguilar L, Sevillano D, Giménez MJ, Cafini F, Valero E, Relaño MT, Prieto J. Alou L, et al. Among authors: gimenez mj. J Antimicrob Chemother. 2006 Apr;57(4):714-9. doi: 10.1093/jac/dkl041. Epub 2006 Feb 21. J Antimicrob Chemother. 2006. PMID: 16492718
Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil.
Sevillano D, Aguilar L, Alou L, Giménez MJ, Torrico M, González N, Cafini F, Relaño MT, Coronel P, Prieto J. Sevillano D, et al. Among authors: gimenez mj. Antimicrob Agents Chemother. 2008 Mar;52(3):1184-6. doi: 10.1128/AAC.01247-07. Epub 2007 Dec 26. Antimicrob Agents Chemother. 2008. PMID: 18160517 Free PMC article.
235 results